Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function.

Vecuronium (initial dose 0.1 mg kg-1; incremental doses 0.04 mg kg-1) was given to 21 normal and 21 anephric patients. There were no gross differences between the two groups in the effect or in the duration of action of either initial or incremental doses, except in two anephric patients who were resistant to the agent. Reversal with neostigmine was satisfactory. In normal patients the initial dose of vecuronium was slower in onset of action than was atracurium 0.5 mg kg-1 (26 patients): the first two incremental doses of vecuronium were administered significantly earlier than the corresponding increments of atracurium (0.2 mg kg-1), but the duration of action of increments over-all was not greatly different. However, in anephric patients, except in the resistant patients, the behaviour of vecuronium was similar to that of atracurium (26 patients). A comparison with an initial dose of tubocurarine 0.5 mg kg-1 given to 20 anephric patients and tubocurarine 0.6 mg kg-1 given to 21 normal and 20 anephric patients showed tubocurarine to be longer acting and considerably less predictable. This was particularly so in the anephric group, in which its action sometimes persisted after neostigmine had been given.

[1]  J. Hunter,et al.  Use of Atracurium in Patients with No Renal Function , 1983 .

[2]  R. Miller,et al.  Neuromuscular Effects of Vecuronium (ORG NC45) in Infants and Children during N2O, Halothane Anesthesia , 1983, Anesthesiology.

[3]  H. H. Ali,et al.  Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium. , 1983, British journal of anaesthesia.

[4]  H. Nagashima,et al.  Muscular relaxation with atracurium, vecuronium and duador under balanced anaesthesia. , 1983, British journal of anaesthesia.

[5]  W. Buzello,et al.  Repetitive administration of pancuronium and vecuronium (Org NC 45, Norcuron) in patients undergoing long lasting operations. , 1982, British journal of anaesthesia.

[6]  P. Lilleaasen,et al.  Dose-response relation for atracurium, ORG NC 45 and pancuronium. , 1982, British journal of anaesthesia.

[7]  R. Miller,et al.  Renal and Biliary Elimination of Vecuronium (ORG NC 45) and Pancuronium in Rats , 1982, Anesthesia and analgesia.

[8]  R. Miller,et al.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure. , 1981, British journal of anaesthesia.

[9]  L. Booij,et al.  Pharmacology of ORG NC 45 compared with other non-depolarizing neuromuscular blocking drugs. , 1980, British journal of anaesthesia.

[10]  H. H. Ali,et al.  Monitoring of neuromuscular function , 1987, International journal of clinical monitoring and computing.

[11]  W. Buzello,et al.  Kinetics of intercompartmental disposition and excretion of tubocurarine, gallamine, alcuronium and pancuronium in patients with normal and impaired renal function. , 1978, Der Anaesthesist.

[12]  H. H. Ali Monitoring of neuromuscular function , 1987, Anesthesiology.

[13]  H. H. Ali,et al.  QUANTITATIVE ASSESSMENT OF RESIDUAL ANTIDEPOLARIZING BLOCK (PART II) , 1971 .

[14]  R. Katz Neuromuscular Effects of d-Tubocurarine, Edrophonium and Neostigmine in Man , 1967, Anesthesiology.